/VIVXF
VIVXF Stock - Avivagen Inc.
Healthcare|Drug Manufacturers - Specialty & GenericOTC
$0.00+0.00%
+$0.00 (+0.00%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.50
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VIVXF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.51
52W High$0.00
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $939,173 | $1.30M | $1.18M | $977,451 | $1.07M |
| Gross Profit | $400,299 | $534,340 | $470,980 | $526,481 | $653,737 |
| Gross Margin | 42.6% | 41.2% | 40.0% | 53.9% | 61.0% |
| Operating Income | $-4,897,756 | $-4,147,617 | $-3,414,270 | $-4,110,362 | $-4,534,883 |
| Net Income | $-6,066,206 | $-6,394,159 | $-4,751,287 | $-4,836,420 | $-4,834,059 |
| Net Margin | -645.9% | -493.4% | -403.4% | -494.8% | -450.7% |
| EPS | $-0.09 | $-0.12 | $-0.12 | $-0.14 | $-0.15 |
Company Overview
Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
VIVXFBeat Rate
0%
Last 8 quarters
Avg Surprise
-24.4%
EPS vs Estimate
Beats / Misses
0/6
2 met exactly
Latest EPS
$-0.01
Q3 2023
EPS Surprise History
Q1 22
0.0%
$-0.02vs$-0.02
Q1 22
-20.0%
$-0.03vs$-0.03
Q2 22
-20.0%
$-0.02vs$-0.02
Q3 22
-20.0%
$-0.02vs$-0.02
Q1 23
-49.9%
$-0.01vs$-0.01
Q1 23
No data
Q2 23
No data
Q3 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Sep 30, 2024 | — | — | — | — |
Q3 2024 | Jul 10, 2024 | — | — | — | — |
Q2 2024 | Apr 29, 2024 | — | — | — | — |
Q1 2024 | Jan 3, 2024 | — | — | — | — |
Q3 2023 | Sep 28, 2023 | — | $-0.01 | — | — |
Q2 2023 | Jun 6, 2023 | — | $-0.01 | — | — |
Q1 2023 | Mar 16, 2023 | — | $-0.01 | — | — |
Q1 2023 | Feb 21, 2023 | $-0.01 | $-0.01 | -49.9% | ✗ MISS |
Q3 2022 | Sep 16, 2022 | $-0.02 | $-0.02 | -20.0% | ✗ MISS |
Q2 2022 | Jun 15, 2022 | $-0.02 | $-0.02 | -20.0% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | $-0.03 | $-0.03 | -20.0% | ✗ MISS |
Q1 2022 | Jan 19, 2022 | $-0.02 | $-0.02 | 0.0% | = MET |
Q3 2021 | Sep 29, 2021 | — | $-0.02 | — | — |
Q2 2021 | Jun 2, 2021 | $-0.02 | $-0.03 | -60.0% | ✗ MISS |
Q1 2021 | Mar 3, 2021 | — | $-0.02 | — | — |
Q4 2020 | Dec 15, 2020 | — | $-0.02 | — | — |
Q3 2020 | Sep 2, 2020 | — | $-0.01 | — | — |
Q2 2020 | Jun 2, 2020 | — | $-0.02 | — | — |
Q1 2020 | Mar 4, 2020 | $-0.04 | $-0.04 | 0.0% | = MET |
Q4 2019 | Dec 19, 2019 | $-0.02 | $-0.03 | -25.0% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about VIVXF
What is VIVXF's current stock price?
Avivagen Inc. (VIVXF) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for VIVXF?
No analyst price targets are currently available for this stock.
What sector is Avivagen Inc. in?
Avivagen Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.
What is VIVXF's market cap?
Avivagen Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does VIVXF pay dividends?
No, Avivagen Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAOXG
Aoxing Pharmaceutical Company, Inc.
$0.00
Mkt Cap: $0.0B
CNNXF
CannAmerica Brands Corp.
$0.00
Mkt Cap: $0.0B
CWWBF
Plant-Based Investment Corp.
$0.00
Mkt Cap: $0.0B
FFNTF
4Front Ventures Corp.
$0.00
Mkt Cap: $0.0B
GBHPF
Global Hemp Group Inc.
$0.01
Mkt Cap: $0.0B
HMPQ
HempAmericana, Inc
$0.00
Mkt Cap: $0.0B
INSO
Industry Source Consulting, Inc.
$0.00
Mkt Cap: $0.0B
PZOO
Pazoo, Inc.
$0.00
Mkt Cap: $0.0B
RLBD
Real Brands, Inc.
$0.00
Mkt Cap: $0.0B
VDRM
ViaDerma, Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to VIVXF for comparison